SBIR/STTR Research Award
A Potent Small Molecule Chemokine Antagonist Blocks Tumor Cell Dissemination In V
Award amount
$224,748Program and phase
SBIR · Phase IAward year
2014Award details
- Awarding agency
- Department of Health and Human Services
- Branch
- National Institutes of Health
- Recipient company
- ALLIANCE DISCOVERY INC
- Proposal award date
- Not reported
- Contract end date
- Not reported
- UEI
- ZJXPXB7JBRH5
- Solicitation number
- PA13-234
- Topic code
- NCI
Research abstract
DESCRIPTION (provided by applicant): Evidence in pre-clinical and clinical settings suggests the involvement of chemokines in metastatic tumor cell disease spreading. We have recently provided data validating the involvement of the CX3CR1/Fractalkine axisin breast and prostate cancer metastasis. We have discovered a potent in vivo efficacious drug-like small molecule using in vitro chemotaxis and functional assays to provide pharmacological proof of concept that modulation of the CX3CR1/ Fractalkine axis with a small molecule CX3CR1 antagonist may have therapeutic benefit in the treatment of advanced breast and prostate cancer. Specific aims of this proposal are: Aim 1: To provide an improved drug-like CX3CR1 antagonist. The lead compound, JMS-17-2, will beoptimized using medicinal chemistry approaches; maintaining potency, improving selectivity, and optimizing in vitro pharmacokinetic properties and the resulting optimized lead from this aim will be evaluated for in vivo pharmacokinetics in mice and u
Technology keywords
Not reported
Other awards by this recipient
Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.
Awards with the same topic code
Verified by an exact topic code match. This is not a text-similarity match.
- Mini-reflectance confocal microscope (Mini-RCM) for aiding skin cancer diagnosis and treatment
- Development of small molecule therapeutics targeting AR-V7 for prostate cancer
- Decentralized Clinical Trial of Effectiveness of EnergyPoints App to Guide Acupressure Use for Fatigue and Sleep Disturbances in Cancer Survivors
- Optimized targeted radiotherapy of pancreatic cancer
- Adaptive imaging for pioneering multiplexed spatial profiling of tumors and tissues for cancer research and diagnosis
Research funding history
2 SBIR/STTR records share this UEI (2014–2017). Reported award amounts total $1,835,930. Reported amounts are not federal obligations.
Phases: Phase II, Phase I
Agencies: Department of Health and Human Services